Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on July 1, 2026 to four new employees under Bicara's 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate, non-qualified stock options to purchase 191,425 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $28.91 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on July 1, 2026.

GlobeNewsWire • Jul 2, 2026

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?

CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20.04 per share on May 18, 2026. This represented 3.98% of Mazumdar's direct holdings prior to the transaction, with post-transaction direct ownership at 362,152 shares.

The Motley Fool • Jun 13, 2026

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics NASDAQ: BCAX said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the company as Ficara, in first-line recurrent or metastatic HPV-negative head and neck cancer.

MarketBeat • May 22, 2026

Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript

Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript

Seeking Alpha • May 22, 2026

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care

GlobeNewsWire • May 21, 2026

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics NASDAQ: BCAX said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference.

MarketBeat • May 14, 2026

Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara's 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara's Chief Commercial Officer.

GlobeNewsWire • May 13, 2026

Bicara Therapeutics Q1 Earnings Call Highlights

Bicara Therapeutics NASDAQ: BCAX said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while reporting a strengthened cash position following a February public offering.

MarketBeat • May 11, 2026

Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript

Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 11, 2026